Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 267 500 KRW 0.38%
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note
Hanmi Pharm Co Ltd
/
Cash Flow Statement
/
Depreciation & Amortization

Hanmi Pharm Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hanmi Pharm Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Pharm Co Ltd
KRX:128940
Depreciation & Amortization
₩97.5B
CAGR 3-Years
6%
CAGR 5-Years
13%
CAGR 10-Years
14%
Yuhan Corp
KRX:000100
Depreciation & Amortization
₩58.1B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
9%
SK Biopharmaceuticals Co Ltd
KRX:326030
Depreciation & Amortization
₩15.3B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Depreciation & Amortization
₩8.9B
CAGR 3-Years
18%
CAGR 5-Years
8%
CAGR 10-Years
22%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Depreciation & Amortization
₩8.8B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
8%
C
Celltrion Pharm Inc
KOSDAQ:068760
Depreciation & Amortization
₩20.5B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
30%
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
373 830.22 KRW
Undervaluation 28%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Hanmi Pharm Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
97.5B KRW

Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's Depreciation & Amortization amounts to 97.5B KRW.

What is Hanmi Pharm Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
14%

Over the last year, the Depreciation & Amortization growth was -2%. The average annual Depreciation & Amortization growth rates for Hanmi Pharm Co Ltd have been 6% over the past three years , 13% over the past five years , and 14% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.